drugset / Trial / NCT03792815
Busulfan, Melphalan and Etoposide as Conditioning for Autologous Transplantation for Non-Hodgkin's Lymphoma (NHL)
NaSingle-groupOpen-labelTreatment
Summary
The investigators developed a protocol utilizing once-daily intravenous busulfan/melphalan/etoposide regimen as a conditioning for high-dose therapy (HDT) in the patients with high risk or relapsed Non-Hodgkin's Lymphoma (NHL).
Timeline
- Start
- 2009-10
- Primary completion
- 2011-11
- Completion
- 2013-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Busulfan | Small molecule | 3.2 mg/kg | Intravenous |
| Subject | Etoposide | Small molecule | 400 mg/m2 | Intravenous |
| Subject | Melphalan | Small molecule | 50 mg/m2 | Intravenous |